Exelixis
Navigation Links
Exelixis in Medical News
SOUTH SAN FRANCISCO, Calif., Dec. 6 /PRNewswire-FirstCall/ -- Exelixis,
Inc. (Nasdaq: EXEL ) announced today that that it will hold an analyst and
investor briefing in conjunction with The American Society of Hematology
48th Annual Meeting from 8:00 p.m. to 9:00 p.m. ET on Monday, December 10...
...bcast and may be accessed in the Event Calendar page under Investors on the exelixis website at http://www.exelixis.com . About Exelixis Exelixis, Inc. is ...udes investigational compounds in phase 2 and phase 1 clinical development. exelixis has established strategic corporate alliances with major pharmaceutical and...
...rrently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb C...
...her investigating that potential in this trial." exelixis and Bristol-Myers Squibb established their joint L...l period of two years. The collaboration calls for exelixis and Bristol-Myers Squibb to jointly identify drug ...activities for such compounds. At time of signing, exelixis received a $17.5 million upfront payment and a com...
... in the Event Calendar page under Investors on the exelixis website at http://www.exelixis.com . About exelixis Exelixis, Inc. is a development-stage biotechnolo...clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with...
... in the Event Calendar page under Investors on the exelixis website at http://www.exelixis.com . About exelixis Exelixis, Inc. is a development-stage biotechnolo...clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with...
Exelixis Reports Phase 1 and Phase 2 Data For XL647 at ASCO
...d Analyst Briefing at ASCO, Monday, June 2, 6 pm exelixis will host an investor and analyst briefing on Mond...ck Place (Regency C&D - 2nd Floor). At this event, exelixis will provide a review of its data presented at ASC...ounds in phase 2 and phase 1 clinical development. exelixis has established strategic corporate alliances with...QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes
... Ltd. (TSE: 4523.T) Encysive Pharmaceuticals Inc. (Nasdaq: ENCY ) Enzo Biochem Inc. (NYSE: ENZ ) ENZON PHARMACEUTICALS INC. (Nasdaq: ENZN ) exelixis Inc. (Nasdaq: EXEL ) Flamel Technologies (Nasdaq: FLML ) Illumina Inc. (Nasdaq: ILMN ) Incyte Corporation (Nasdaq: INCY ) Integra LifeScie......bcast and may be accessed in the Event Calendar page under Investors on the exelixis website at http://www.exelixis.com . About Exelixis Exelixis, Inc. is ...udes investigational compounds in phase 2 and phase 1 clinical development. exelixis has established strategic corporate alliances with major pharmaceutical and...
...rrently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb C...
...her investigating that potential in this trial." exelixis and Bristol-Myers Squibb established their joint L...l period of two years. The collaboration calls for exelixis and Bristol-Myers Squibb to jointly identify drug ...activities for such compounds. At time of signing, exelixis received a $17.5 million upfront payment and a com...
... in the Event Calendar page under Investors on the exelixis website at http://www.exelixis.com . About exelixis Exelixis, Inc. is a development-stage biotechnolo...clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with...
Exelixis Announces October 10 Webcast of Presentation at the 2007 Bio InvestorForum Conference
... in the Event Calendar page under Investors on the exelixis website at http://www.exelixis.com . About exelixis Exelixis, Inc. is a development-stage biotechnolo...clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with...... in the Event Calendar page under Investors on the exelixis website at http://www.exelixis.com . About exelixis Exelixis, Inc. is a development-stage biotechnolo...clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with...
Exelixis Commences Public Offering of Common Stock
... effective automatic shelf registration statement. exelixis will also grant the underwriter a 30-day option to...nder the securities laws of any such state. About exelixis Exelixis, Inc. is a development-stage biotechnolo...he public offering. There can be no assurance that exelixis will complete the offering of the common stock on ...Exelixis in Medical Technology
Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
- Phase I data from XL880, Phase II data from XL999 studies scheduled for presentation during oral, poster sessions - SOUTH SAN FRANCISCO, May 30, 2007 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that data from clinical trials of the company's investigational compounds XL880 and XL999......ounds in phase 2 and phase 1 clinical development. exelixis has established strategic corporate alliances with...mstances on which any such statements are based. exelixis and the exelixis logo are registered U.S. trademarks. ...
Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO
...d Analyst Briefing at ASCO, Monday, June 2, 6 pm exelixis will host an investor and analyst briefing on Mond...ck Place (Regency C&D - 2nd Floor). At this event, exelixis will provide a review of its data presented at ASC...ounds in phase 2 and phase 1 clinical development. exelixis has established strategic corporate alliances with...Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
...Analyst Briefing at ASCO, Monday, June 2, 6 p.m. exelixis will host an investor and analyst briefing on Mond...ck Place (Regency C&D - 2nd Floor). At this event, exelixis will provide a review of its data presented at ASC...ounds in phase 2 and phase 1 clinical development. exelixis has established strategic corporate alliances with...Exelixis Announces First Quarter 2008 Financial Results
...7 and XL880*). * The technology transfer by exelixis to GlaxoSmithKline (GSK) in connection with GSK...ounds in phase 2 and phase 1 clinical development. exelixis has established strategic corporate alliances with...nces on which any such statements are based. exelixis and the...GSK Does Not Option XL784 for Further Development
...784 for further development and commercialization. exelixis previously announced that XL784 failed to meet its...ns to choose XL784. As a result of GSK's decision, exelixis has the right to develop and commercialize XL784 e...clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with...Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
...s in phase 2 and phase 1 clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with major pharmaceutical and...07 and Exelixis' other filings with the Securities and Exchange Commission. exelixis expressly disclaims any duty, obligation or undertaking to release publicly...Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
...rrently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb C...... is the first small molecule compound developed by exelixis using its proprietary drug discovery engine. The c...active safety and pharmacokinetic profiles. About exelixis Exelixis, Inc. is a development-stage biotechnolo...clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with...
Interim Phase 2 Data for Exelixis' XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
...evelopment and commercialization agreement between exelixis and GlaxoSmithKline (GSK), GSK has the option, aft...a, gastric cancer and head and neck cancer. About exelixis Exelixis, Inc. is a development-stage biotechnolo...clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with...Exelixis in Biological Technology
REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO
Seven Abstracts Accepted for Presentation at ASCO SOUTH SAN FRANCISCO, Calif., May 28 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL ) will hold an investor and analyst briefing in conjunction with the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) ...Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting
Two oral presentations, two poster discussion presentations, three poster presentations SOUTH SAN FRANCISCO, Calif., March 31 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL ) announced today that data from clinical trials of the company's investigational com...Option to Develop Exelixis Compound Exercised By Genentech
SOUTH SAN FRANCISCO, Calif., March 14 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL ) today announced that Genentech, Inc. has exercised its option to further develop and commercialize Exelixis' compound XL518, a selective and potent inhibitor of MEK, which is currently in a phase 1 ...Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
SOUTH SAN FRANCISCO, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL ) announced today that it will hold its Third Annual R&D Day on Wednesday, December 5, 2007 from 10:00 a.m. ET / 7:00 a.m. PT to 2:00 p.m. ET / 11:00 a.m. PT in New York. The company will discuss updat...INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW ), and Exelixis Plant Sciences, a wholly owned subsidiary of Exelixis, Inc. (Nasdaq: EXEL ), announced today that the compani...
Sanofi-aventis Announces Second Quarter 2009 Results
... in triple negative breast cancer; license and collaboration agreement with exelixis Exploring external growth opportunities : significant boost to our ...r both of these products, which were developed by the biotechnology company exelixis SAR 407899, a rho-kinase inhibitor, entered Phase II in...iZumi Bio Appoints Dr. Corey Goodman to Board of Directors and Scientific Advisory Board
...is from 2001 until 2007, when the company merged with Evotec. He has advised numerous biotechnology companies, and co-founded two companies, including exelixis and Renovis. Dr. Goodman was a professor at Stanford University and the University of California, Berkeley for over two decades, and is curr...... exelixis Generated 10 IND Compounds and Received over $235 ... will be limited to the compounds selected by GSK. exelixis will have the right to perform additional discover...ship of the compounds in our pipeline." To date, exelixis has received approximately $235 million from GSK, ...
Exelixis Announces June 25 Webcast of Presentation at the Piper Jaffray Europe Conference
...bcast and may be accessed in the Event Calendar page under Investors on the exelixis website at http://www.exelixis.com . About Exelixis Exelixis, Inc. is ...udes investigational compounds in phase 2 and phase 1 clinical development. exelixis has established strategic corporate alliances with major pharmaceutical and...Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes
...APUTICS GROUP PLC (London Main Market, U.K.: AKT) exelixis INC. (NASDAQ: EXEL ) HUMAN GENOME SCIENCES INC. ...NYSE: CVD ) DAINIPPON SUMITOMO (Tokyo SE: 4506) exelixis INC (NASDAQ: EXEL ) FRESENIUS SE (Frankfurt, Ger...: BGC) COUGAR BIOTECHNOLOGY INC (NASDAQ: CGRB ) exelixis INC (NASDAQ: EXEL ) LIGAND PHARMACEUTICALS INC (...Other TagsAdvancementDesertPeregrineNicoleOther Contentssouthernsouthernsouthernsouthernsouthernsouthernspermatidsspermatogoniafibersfibersfibersfibersfibersfiberssphinctersphinctersphinctersphincternervenervenervenervenervenervenervenervenervespinalspinalspinalspinalspinalspinalspinalspinal
PotterBritsKnightleyAdvancementTimberlakeDesertGalapagosPeregrineNovagaliBlundersReplidyneGenopoleNicoleNepalese
(Date:12/15/2009)... Leading Workers, Compensation Carrier Confirms PMSI as Solution Provider ... ... Tampa, FL (Vocus) December 15, 2009 -- PMSI, ... providers of specialty products and services for the workers’ ... (KEMI) has decided to renew its pharmacy services (retail ...
(Date:12/15/2009)... mental health care still needed for those with the ... -- Suicides among people in Switzerland who were infected ... introduction of highly active antiretroviral therapy in 1996, a ... causes AIDS. , Yet despite the decrease, the suicide ... than that of the general population, according to the ...
(Date:12/15/2009)... Dec. 15 Connectyx Technologies Holding Group ... has moved to a higher listing level on ... The higher move positions Connectyx as a Transparent ... ,, Connectyx President Ronn Schuman stated, "We ... of our efforts to become a fully reporting ...
(Date:12/15/2009)... HONG KONG, Dec. 15 /PRNewswire-Asia/ --, Key points:, ... Cells (South) Company, Limited with ... exclusive access to about 1 million new births, ... -- CordLife,s geographical footprint in Asia Pacific is enlarged, with, ... India, two of the largest and fastest, ...
(Date:12/15/2009)... , ... Alpharetta, GA (Vocus) Dec. 14, 2009 -- Staffing ... and CRNA staffing, as the #4 Best Staffing Firm to Work ... proud to be recognized on this list because it highlights how ... Jackson president of LocumTenens.com. “Unquestionably, we know that our associates are ...
Breaking Medicine News(10 mins):Health News:KEMI Renews Contract With PMSI 2Health News:HIV Therapy Linked to Fewer Suicides 2Health News:Connectyx Attains 'Current Listing' Status on Pink Sheets Exchange 2Health News:Connectyx Attains 'Current Listing' Status on Pink Sheets Exchange 3Health News:CordLife Secures Strategic Presence in China 2Health News:CordLife Secures Strategic Presence in China 3Health News:LocumTenens.com Named 4th Best Staffing Firm to Work For 2(Date:12/14/2009)... of the proteins in a species of salamander that ... similar regeneration could be induced in humans. , ... University Indianapolis and colleagues investigated over three hundred proteins ... salamander that has the unique natural ability to regenerate ... that this knowledge will contribute to a better understanding ...
(Date:12/14/2009)... feature of humans. That,s until examples of tool use came ... of other mammals. Now, a report in the December 14th ... adds an octopus to the growing list of tool users. ... that the researchers call stilt walking. In it, the soft-bodied ... its eight arms rigid, and raises the whole assembly to ...
(Date:12/14/2009)... laparoscopy is in preventing some of the stresses of open ... blood flow and organ dysfunction. Laparoscopy is a type of ... , By adding another gas to the carbon ... at Duke University Medical Center have found they can preserve ... gas ethyl nitrite (ENO) helped to open blood vessels and ...
Breaking Biology News(10 mins):IUPUI researchers tackle protein mechanisms behind limb regeneration 2Tool use in an invertebrate: The coconut-carrying octopus 2Gas improves blood flow and organ status during minimally invasive surgery 2Go and Good Things Happen with 28BUGABOO 29 28RED 29 56537 1Go and Good Things Happen with 28BUGABOO 29 28RED 29 56537 2Go and Good Things Happen with 28BUGABOO 29 28RED 29 56537 3Go and Good Things Happen with 28BUGABOO 29 28RED 29 56537 4WomenHeart and P A D Coalition Join Forces to Educate Women about Peripheral Arterial Disease 56532 1WomenHeart and P A D Coalition Join Forces to Educate Women about Peripheral Arterial Disease 56532 2WomenHeart and P A D Coalition Join Forces to Educate Women about Peripheral Arterial Disease 56532 3Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 1Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 2Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 3Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 4Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 5Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 6Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 7| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |